Southampton Clinical Trials Unit, University of Southampton, Southampton General Hospital, Southampton, UK.
Southampton Clinical Trials Unit, University of Southampton, Southampton General Hospital, Southampton, UK.
Clin Oncol (R Coll Radiol). 2022 Aug;34(8):e329-e344. doi: 10.1016/j.clon.2022.02.015. Epub 2022 Mar 11.
Platinum-based chemotherapy forms the backbone of treatment for many solid cancers. However, resistance inevitably develops in those with advanced disease. Platinum rechallenge is a well-established concept in the management of ovarian cancer, small cell lung cancer and germ cell tumours. In other solid malignancies there is a lack of quality evidence to support platinum rechallenge, yet it is a widely adopted strategy. Often, patients are within the last year of life, making questions of efficacy, treatment-related toxicity and quality of life critical factors for treatment recommendations. In this overview we appraise the available evidence for platinum rechallenge and strategies being developed to attempt resensitisation of tumours to platinum-based chemotherapy.
铂类化疗是许多实体瘤治疗的基础。然而,晚期疾病患者不可避免地会产生耐药性。铂类药物再挑战在卵巢癌、小细胞肺癌和生殖细胞瘤的治疗管理中是一个成熟的概念。在其他实体恶性肿瘤中,缺乏支持铂类药物再挑战的高质量证据,但这是一种广泛采用的策略。通常,患者处于生命的最后一年,因此疗效、治疗相关毒性和生活质量是治疗建议的关键因素。在这篇综述中,我们评估了铂类药物再挑战的现有证据,并探讨了试图使肿瘤对铂类化疗重新敏感的策略。